At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 9 enrolled
Drug / intervention
Metvix PDTprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® PDT
In Brief
A Phase 4 clinical trial evaluating Metvix PDT for Actinic Keratosis. Completed, enrolled 9 participants across 1 site.
Detailed Summary
The aim of this study is to determine possible molecular changes on large scale gene expression profiling after treatment with Metvix photodynamic therapy (PDT) of actinic keratoses (AK) and cancerised field in renal transplant recipients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsActinic Keratosis
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2009
First PostedOct 2009
Primary CompletionOct 2011
TodayJul 2026
First PostedOct 23, 2009
Enrollment StartOct 1, 2009
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 16.7 years ago
Interventions
Metvix PDTprocedure
Methyl aminolevulinate cream will be applied for 3 hours on the whole target field. The target field will then be exposed to red light using Aktilite 128 lamp.